Roche's new drug boosts stock price to its highest monthly level in 28 years! Investors returning to value stocks are fueling a "collective frenzy" in the healthcare sector.

According to the Wall Street Journal app, the optimistic sentiment surrounding Roche's experimental breast cancer drug, as well as encouraging trial results, have driven the company's stock price to its best monthly performance since 1997. At the same time, analysts predict that the stock price still has room to rise.